Sign in

    Dennis Chu

    Managing Director and Senior Equity Research Analyst at Jefferies

    Dennis Chu is a Managing Director and Senior Equity Research Analyst at Jefferies, focusing on Real Estate Investment Trusts (REITs), particularly within the retail and specialty sectors. He covers key publicly traded companies such as Simon Property Group, Kimco Realty, Realty Income, and Regency Centers, and has earned recognition for his accurate investment recommendations, achieving a success rate around 67% and average annual returns exceeding 12% for his stock picks as tracked by TipRanks. Chu started his career in financial analysis in the late 2000s, previously working at Merrill Lynch before joining Jefferies in 2011, where he has steadily advanced to his current senior role. He is FINRA-registered, holding Series 7, 63, and 86/87 licenses, and is noted for his in-depth industry insights and respected position among institutional investors.

    Dennis Chu's questions to RECURSION PHARMACEUTICALS (RXRX) leadership

    Dennis Chu's questions to RECURSION PHARMACEUTICALS (RXRX) leadership • Q1 2025

    Question

    Dennis Chu of Jefferies, along with analysts from Needham, Bank of America, and Cowen, asked for details on the FAP data, its differentiation from other programs, the case of the non-responder, and the bar for success.

    Answer

    Chief R&D Officer Najat Khan reported that preliminary data showed a 43% median polyp burden reduction, comparing favorably to the 20-30% seen with other agents. She noted the safety profile is consistent with the MEK1/2 inhibitor class. Regarding the non-responder, she explained that non-response rates of 40-50% have been seen in prior studies. The bar for success is high given the significant unmet need.

    Ask Fintool Equity Research AI